Biophytis Reports First-Half 2025 Results and Provides Strategic Update

Paris, France, Cambridge (Massachusetts, United States), October 30th, 2025 – 11:00 p.m. CET – Biophytis SA ("the Company"), a pioneering company in the development of transformative therapies impacting longevity, today reports its financial results for the first half of 2025 and provides an update on its strategic outlook.

Stanislas Veillet, Chief Executive Officer of Biophytis, stated: *"The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture in Asia, we are paving the way for the world's first Phase 3 clinical trial in sarcopenia. At the same time, EMBRAPII's support in Brazil for our Phase 2 obesity trial confirms the potential of BIO101 in combination with GLP-1 therapies. These tangible advances, together with the planned strengthening of our research platform, position Biophytis to sustainably improve the lives of millions of patients and create long-term value for our shareholders."*

Highlights of the First Half of 2025

Acceleration of the Roadmap in Sarcopenia

After announcing early this year the start of exclusive negotiations with Chinese partners for the co-development of BIO101 in sarcopenia, Biophytis recently disclosed that discussions led to the signing of a memorandum of understanding with a consortium of investors including Ronghui Renhe Life Technology, a Chinese conglomerate mainly involved in pharmaceutical distribution and healthcare products.

This agreement paves the way for the creation of a joint venture headquartered in Hong Kong, dedicated to financing and launching the world's first Phase 3 clinical trial in sarcopenia. The joint venture will hold exclusive rights to develop and commercialize BIO101 in China, Japan, and South Korea, with an investment of up to USD 20 million from the consortium over the next two years.

Major Advances in Obesity

During the first half of 2025, Biophytis announced new preclinical results on the treatment of muscle loss in obese patients, presented at the 15th International Conference on Frailty and Sarcopenia. In this study, Biophytis again demonstrated that BIO101, in combination with GLP-1 therapies, plays a key role in preserving muscle strength (grip) and mobility (endurance).

In addition, Biophytis announced financial support from EMBRAPII, a Brazilian government-backed innovation agency whose mission is to promote industrial R&D collaboration and accelerate clinical innovation. This partnership provides non-dilutive funding for the Phase 2 OBA study, reducing the Company's cash needs while confirming the strategic importance of the program at the national level.

Biophytis' Strategic Roadmap

The Company's strategy is structured around three main pillars:

- **Upcoming launch of a Phase 2 study in obesity:** Biophytis will soon initiate the Phase 2 OBA study to evaluate the efficacy of BIO101 (20-hydroxyecdysone) in combination with GLP-1 receptor agonists in obese patients. This study aims to address a critical issue: preserving muscle mass while promoting weight loss. The clinical development will take place in the U.S., Brazil, and Europe, where patient needs are the greatest.

- **Upcoming launch of a Phase 3 study in sarcopenia:** Biophytis also intends to initiate the Phase 3 study of its SARA program, which will be the first in the world in this indication. The study will be conducted in Europe and Asia to address the surge in sarcopenia cases in these regions and access the most promising markets.

- **Strengthening of the drug discovery platform:** Biophytis will modernize its research platform to accelerate the identification of new promising molecules in the field of longevity, reinforcing its pipeline, innovation capacity, and ability to identify new candidates and explore new therapeutic targets. The integration of disruptive technologies and the use of artificial intelligence to accelerate discovery will be prioritized.

Financing the Roadmap

In line with its business model, Biophytis will continue to actively pursue new partnership and collaboration opportunities across the Americas, Europe, and Asia, following the examples of its licensing and co-development agreements with Blanver for Latin America and with a consortium of investors in China. The Company also strengthened its equity base twice during the first half of 2025 and intends to maintain this trend to finance its R&D programs in key indications, notably obesity and sarcopenia, as well as the modernization of its drug discovery platform.

Key Financial Elements of the First Half of 2025

Cash Position Sufficient for the Next Five Months

Consolidated cash amounted to €1.2 million as of June 30, 2025, compared to €2.2 million as of June 30, 2024, representing a net decrease of €1 million. Cash used in operating activities totaled €2.9 million.

As of the date of approval of these financial statements, and based on current operations, plans, and assumptions reviewed by the Board of Directors on October 30, 2025, the Company estimates that it can finance its activities until the first quarter of 2026. Therefore, cash and cash equivalents do not allow the Company to finance its operations over the next 12 months, creating a material uncertainty regarding its ability to continue as a going concern.

Equity and Debt

During the first half of 2025, the Company strengthened its equity and cash position through two operations: On January 8, 2025, a first transaction brought in €2.5 million in cash and included a debt conversion of up to €6.1 million ; On March 26, 2025, a €2.6 million private placement was completed with qualified investors.

Convertible debt evolution since January 2025 (in € thousands):

K€	Initial Debt	Conversion into Shares	Remaining Debt (10/30)
ATLAS	2,883	2,446	437
KREOS	2,804	1,794	1,010
Total	**5,687**	**4,240**	**1,447**

In August 2025, the Company also announced the establishment of a new bond financing line of up to €1 million.

Reduced Half-Year Loss

Operating expenses decreased significantly by €0.3 million, mainly due to a €0.8 million reduction in R&D expenditures. The €0.5 million increase in administrative and financial expenses was due to costs incurred for debt refinancing operations and capital increases.

The positive change in financial result (+€2 million) compared to June 30, 2024, is primarily related to the restructuring of financial liabilities in accordance with IFRS 9.

The net loss for the first half of 2025 amounted to €3.3 million, a reduction of €2.3 million compared to June 30, 2024.

Consolidated Results

(in € thousands)	30/06/2024	30/06/2025
Revenue		
R&D expenses, net	2,105	1,312
General and Administrative expenses	2,285	2,745
Operating Result	**4,390**	**4,057**
Financial Result	1,427	**- 594**
Net Result (loss)	**5,817**	**3,463**

- As a result, the half-year loss amounts to €3.4 million.

***

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA).

We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

Biophytis Contacts

Investor Relations
Investors@biophytis.com

US Investors
Pascal Nigen – Alpha Bronze
pnigen@alphabronzellc.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78